Released February 24, 2021 | CORDOBA, ARGENTINA
en
Two bioscience companies are planning major investments in Puerto Rico, citing government incentives.
CytoImmune Therapeutics is planning to invest $28 million in Toa Baja for the construction of a plant to research, develop and produce cancer immunotherapy products. Construction is expected to begin during the last quarter of 2021, with completion and startup set for about a year later.
Biosimilar Solutions is investing $200 million in a new facility in Aguadilla. The project, which is expected to kick off construction this year and to be completed during the third quarter of 2022, aims to develop and produce biosimilar products, including a COVID-19 vaccine, new cell and gene therapies, and biologics.
Click here for a list of active final-formulation projects across Puerto Rico, and see graph below for a breakdown by plant owner.
CytoImmune Therapeutics is planning to invest $28 million in Toa Baja for the construction of a plant to research, develop and produce cancer immunotherapy products. Construction is expected to begin during the last quarter of 2021, with completion and startup set for about a year later.
Biosimilar Solutions is investing $200 million in a new facility in Aguadilla. The project, which is expected to kick off construction this year and to be completed during the third quarter of 2022, aims to develop and produce biosimilar products, including a COVID-19 vaccine, new cell and gene therapies, and biologics.
Click here for a list of active final-formulation projects across Puerto Rico, and see graph below for a breakdown by plant owner.
